ArticleClinical pharmacokinetics2024

Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE

Mukul Minocha et al.PubMed ↗Publisher ↗

No numbers read from the abstract.